| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6387383 | BAUSCH | Topical low-viscosity gel composition |
Aug, 2020
(3 years ago) | |
Clindagel is owned by Bausch.
Clindagel contains Clindamycin Phosphate.
Clindagel has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Clindagel are:
- US6387383
Clindagel was authorised for market use on 27 November, 2000.
Clindagel is available in gel;topical dosage forms.
Clindagel can be used as topical treatment of acne vulgaris.
The generics of Clindagel are possible to be released after 03 August, 2020.
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 27 November, 2000
Treatment: Topical treatment of acne vulgaris
Dosage: GEL;TOPICAL
More Information on Dosage
CLINDAGEL family patents
